Logo

Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies

Share this

Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies

Shots:

  • Editas & BlueRock enter in to research collaboration to develop engineered cell therapies/ allogeneic pluripotent stem cell (PSC) lines by the combination of Editas’ CRISPR & BlueRock’s iPSC in oncology & neurology- cardiology and immunology respectively
  • According to cross-licensing agreement- BlueRock to get non-exclusive & IPR rights for Editas Medicine’s CRISPR technology and Editas to get non-exclusive & IPR rights for BlueRock’s iPSC and cell differentiation technology. The companies will also receive development- regulatory and commercial milestones & royalties on global sales of products
  • Editas’ CRISPR is a genome editing technology utilizes Cas9 or Cpf1 protein to repair broken genes. BlueRock’s iPSC is the basis of CELL+GENE platform used to replace damaged or degenerated tissue to restore or regenerate lost function

Ref: Editas Medicine | Image: PMLive

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions